FPFernando Pico

Fernando Pico

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fernando Pico has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Significance of the Hyperintense Reperfusion Marker and Ocular Gadolinium Leakage After Thrombectomy

    by Camile Bousfiha, Gabriele Vinacci, Julie Gratieux, Intissar Hmida, Marie-Laure Chadenat, Bertrand Lapergue, Adrien Wang, Arturo Consoli, Fernando Pico

    Background and ObjectivesDespite successful recanalization after mechanical thrombectomy for acute ischemic stroke, a substantial proportion of patients experience early neurologic deterioration or...


  • IV Tenecteplase Before Thrombectomy Compared With Thrombectomy Alone in Patients With Stroke Due to a Large Vessel Occlusion

    by Gaspard Gerschenfeld, Bertrand Lapergue, Pierre Seners, Michel Piotin, Nicolas Chausson, Luca Scarcia, Caroline Arquizan, Vincent Costalat, Stephane Olindo, Gaultier Marnat, et al.

    The benefit of IV thrombolysis (IVT) with alteplase before endovascular thrombectomy (EVT) compared with EVT alone has been shown to be limited and time dependent. Data on tenecteplase, its recommended alternative, are limited. We aimed to assess the efficacy and safety of IVT with tenecteplase plus mechanical thrombectomy (TNK + EVT) compared with EVT in patients with large vessel occlusion stroke and determine whether its potential benefit decreases with treatment time. We conducted a retrospective pooled analysis of 2 nationwide, real-world registries of patients with anterior circulation large vessel occlusion stroke within 4.5 hours of known symptom onset and with no contraindication to thrombolysis, treated with TNK + EVT (TETRIS) or EVT (ETIS). The efficacy outcome was the 3-month modified Rankin Scale (mRS) score, analyzed in ordinal and dichotomized (mRS score ≤2) approaches. We used propensity score-weighted logistic regression to assess associations between treatment groups and outcomes of interest. Among 1,890 patients who were analyzed (TNK + EVT: n = 798; EVT: n = 1,092; median age 73 years [interquartile range 61-82]; 49.6% women), the median expected onset-to-thrombolysis time was 146 minutes [interquartile range 119-180]. More than half of patients (n = 1,063; 56.2%) were admitted first to a primary stroke center. All baseline characteristics were balanced between treatment groups after overlap weighting. Overall, TNK + EVT was associated with better 3-month functional outcome over the full mRS (weighted common odds ratio [OR] 1.53 [95% CI 1.29-1.82]; p < 0.001) and regarding functional independence (propensity score overlap weighting [PSOW]-OR 1.50 [95% CI 1.23-1.84]; p < 0.001). This benefit did not differ statistically between patients admitted first to a primary or comprehensive stroke center (p-interaction = 0.12). There was no significant effect of the expected onset-to-thrombolysis time on the association between TNK + EVT and better functional outcome (p-interaction = 0.11). There were no significant differences in parenchymal hematoma (PSOW-OR 1.29 [95% CI 0.94-1.79]; p = 0.12) and symptomatic intracerebral hemorrhage (PSOW-OR 1.13 [95% CI 0.69-1.86]; p = 0.61) rates. Among patients treated within 4.5 hours of symptom onset, TNK + EVT was associated with better functional outcome than EVT, without safety concerns. This benefit does not seem to be time dependent. These findings support the routine use of tenecteplase before EVT in the early time window. This study provides Class II evidence that, in patients with stroke due to anterior circulation large vessel occlusion, IV tenecteplase plus thrombectomy is associated with better functional outcomes at 3 months compared with thrombectomy alone. NCT03776877 (ETIS registry) and NCT05534360 (TETRIS registry).


  • Open Access

    The effect of pre-stroke physical activity on the initial volume and growth of the brain infarct and the rate of recanalization: A post-hoc analysis of the rescue brain trial

    by B. Douma, M. Ferrigno, E. Drumez, B. Lapergue, C. Rosso, E. Meseguer, M.L. Chadenat, M. Obadia, C. Hirel, D.L. Duong, et al.

  • Hyperintense acute reperfusion marker and gadolinium leakage in ocular structures in stroke: a systematic review

    by Camile Bousfiha, Luigi Francesco Saccaro, Arturo Consoli, Fernando Pico

    Introduction The Hyperintense Acute Reperfusion Marker (HARM) and Gadolinium Leakage in Ocular Structures (GLOS) are pivotal radiological findings in post-contrast fluid-attenuated inversion recovery imaging (pcFLAIR), attesting to gadolinium leakage into the cerebrospinal fluid (CSF) in various neurological disorders. Often observed following acute strokes, HARM and GLOS, however, exhibit considerable variability in their prevalence ranging from 5.5 to 85% and 30–76%, respectively. Given their similarity and association of HARM with poor outcomes in stroke, accurately evaluating these markers may be crucial for advancing our understanding of stroke pathophysiology and improving clinical management. Our work aims to identify the major methodological challenges and confounding factors limiting the understanding of HARM and GLOS in stroke. Methods To address these issues, we thoroughly conducted a literature search in Embase, Scopus, and PubMed until July 2022. Our search yielded 38 stroke studies, with only 6 evaluating GLOS. Guided by major findings, we adapted the Newcastle-Ottawa scale for bias risk assessment. Effect estimates were synthetized considering cohort size, statistical significance, and bias risk. Results Methodological issues emerged from the lack of time-specific data, omission of differential CSF hyperintensities, imprecise definitions, and overlooking of adjusting variables like assessment timing, contrast dosages or renal function. Discrepancy results mainly arise from an inadequate time window of investigation, and further research should stratify patients based on the timing of gadolinium injection. Conclusion Our findings emphasize the importance of a more detailed exploration of their timing and localization, rather than simply their binary presence, extent, or severity.


  • Interfacility Transfer for Thrombectomy: A Promising Therapeutic Window

    by Pierre Seners, Jean-Claude Baron, Anke Wouters, Jean-Philippe Desilles, Fernando Pico, Richard Macrez, Jean-Marc Olivot, Robin Lemmens, Gregory W. Albers, Maarten G. Lansberg

    Currently, most acute ischemic stroke patients presenting with a large vessel occlusion are first evaluated at a nonthrombectomy-capable center before transfer to a comprehensive stroke center that performs thrombectomy. Interfacility transfer is a complex process that requires extensive coordination between the referring, transporting, and receiving facilities. As a result, long delays are common, contributing to poor clinical outcomes. In this review, we summarize the accumulating literature about the clinical as well as radiological—infarct growth, collateral change, arterial recanalization, and hemorrhagic transformation—changes during interfacility transfer for thrombectomy. Recent evidence shows that clinical/radiological changes during transfer are heterogeneous across patients and impact long-term functional outcomes, highlighting the urgent need to optimize care during this time window. We review some of the most promising therapeutic strategies—for example, penumbral protection to reduce infarct growth—that may improve clinical outcome in patients being transferred to thrombectomy-capable centers. Finally, we discuss key methodological considerations for designing clinical trials aimed at reducing infarct growth during transfer.


  • Multiple Susceptibility-Weighted Imaging Hypointensities in Intravascular Large B-Cell Lymphoma

    by Fiene Marie Kuijper, Chantal Nifle, Maxime de Malherbe, Carole Soussain, Fernando Pico


  • Cerebral Amyloid Angiopathy–Related Inflammation and Biopsy-Positive Primary Angiitis of the CNS

    by Lou Grangeon, Grégoire Boulouis, Jean Capron, Fouzi Bala, Dimitri Renard, Nicolas Raposo, Ozlem Ozkul-Wermester, Aude Triquenot-Bagan, Xavier Ayrignac, David Wallon, et al.

    Cerebral amyloid angiopathy-related inflammation (CAA-RI) and biopsy-positive primary angiitis of the CNS (BP-PACNS) have overlapping clinicoradiologic presentations. It is unknown whether clinical and radiologic features can differentiate CAA-RI from BP-PACNS and whether both diseases have different relapse rates. The objectives of this study were to compare clinicoradiologic presentations and relapse rates in patients with CAA-RI vs BP-PACNS. Patients with CAA-RI and BP-PACNS were enrolled from 2 retrospective multicenter cohorts. Patients with CAA-RI were biopsy-positive or met probable clinicoradiologic criteria. Patients with BP-PACNS had histopathologic confirmation of CNS angiitis, with no secondary etiology. A neuroradiologist read brain MRIs, blinded to the diagnosis of CAA-RI or BP-PACNS. Clinicoradiologic features were compared using univariable logistic regression models. Relapse rates were compared using a univariable Fine-Gray subdistribution hazard model, with death as a competing risk. This study enrolled 104 patients with CAA-RI (mean age 73 years, 48% female sex) and 52 patients with BP-PACNS (mean age 45 years, 48% female sex). Patients with CAA-RI more often had white matter hyperintense lesions meeting the probable CAA-RI criteria (93% vs 51%, p < 0.001), acute subarachnoid hemorrhage (15% vs 2%, p = 0.02), cortical superficial siderosis (27% vs 4%, p < 0.001), ≥1 lobar microbleed (94% vs 26%, p < 0.001), past intracerebral hemorrhage (17% vs 4%, p = 0.04), ≥21 visible centrum semiovale perivascular spaces (34% vs 4%, p < 0.01), and leptomeningeal enhancement (70% vs 27%, p < 0.001). Patients with BP-PACNS more often had headaches (56% vs 31%, p < 0.01), motor deficits (56% vs 36%, p = 0.02), and nonischemic parenchymal gadolinium enhancement (82% vs 16%, p < 0.001). The prevalence of acute ischemic lesions was 18% in CAA-RI and 22% in BP-PACNS (p = 0.57). The features with the highest specificity for CAA-RI were acute subarachnoid hemorrhage (98%), cortical superficial siderosis (96%), past intracerebral hemorrhage (96%), and ≥21 visible centrum semiovale perivascular spaces (96%). The probable CAA-RI criteria had a 71% sensitivity (95% CI 44%-90%) and 91% specificity (95% CI 79%-98%) in differentiating biopsy-positive CAA-RI from BP-PACNS. The rate of relapse in the first 2 years after remission was lower in CAA-RI than in BP-PACNS (hazard ratio 0.46, 95% CI 0.22-0.96, p = 0.04). Clinicoradiologic features differed between patients with CAA-RI and those with BP-PACNS. Specific markers for CAA-RI were hemorrhagic signs of subarachnoid involvement, past intracerebral hemorrhage, ≥21 visible centrum semiovale perivascular spaces, and the probable CAA-RI criteria. A biopsy remains necessary for diagnosis in some cases of CAA-RI. The rate of relapse in the first 2 years after disease remission was lower in CAA-RI than in BP-PACNS.